Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC 97 Earnings per Share (Diluted) is kr81.31 as of Jun. 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 97/100 and a GF Value™ of kr2,152.09 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,160 Biotechnology companies, Genmab AS ranks worse than 56.64% on this metric.
Genmab AS's EPS (Basic) for the
three
months ended in Jun. 2026 was kr32.06.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr82.40.
Genmab AS's EPS without NRI for the
three
months ended in Jun. 2026 was kr34.27.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr103.20.
During the past 12 months, Genmab AS's average EPS without NRIGrowth Rate was -14.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 11.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 14.40% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 24.40% per year.
During the past 13 years, Genmab AS's highest 3-Year average EPS without NRI Growth Rate was 118.50% per year. The lowest was -14.60% per year. And the median was 20.15% per year.
Genmab AS (CHIX:GMABc) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Genmab AS Earnings per Share (Diluted) Related Terms
Genmab AS Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Genmab AS's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Genmab AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's PE Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's PE Ratio falls into.
Genmab AS Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Genmab AS's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr81.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr81.31 mean?
Genmab AS (CHIX:GMABC) has a Earnings per Share (Diluted) of kr81.31 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Genmab AS and its competitors. According to the industry distribution chart, Genmab AS ranks #657 out of 1160 companies in the Biotechnology industry, placing it in the top 56.6%.
Is Genmab AS's Earnings per Share (Diluted) too high?
Genmab AS's current Earnings per Share (Diluted) is kr81.31. Based on the distribution chart, Genmab AS ranks #657 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #657 out of 1160 companies for Earnings per Share (Diluted). This places Genmab AS in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Earnings per Share (Diluted) is kr81.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,152.09, compared to a current price of kr2,163.00 — trading 0.5% above its estimated fair value. The current Earnings per Share (Diluted) is kr81.31. Genmab AS's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Earnings per Share (Diluted) is kr81.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be overvalued.
The current stock price of kr2,163.00 is trading 0.5% above its estimated GF Value™ of kr2,152.09.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
Earnings per Share (Diluted): kr81.31
GF Value™: kr2,152.09 vs. price of kr2,163.00 (0.5% above fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score
Get the complete analysis for CHIX:GMABC
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
